Cybin to Participate at the 27th Annual Milken Institute Global Conference
25 Abril 2024 - 6:30AM
Business Wire
- Doug Drysdale, CEO, to appear on panel
entitled “Collaborating for Improved Mental Health,” on May 8, 2024
-
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin”
or the “Company”), a clinical-stage biopharmaceutical
company committed to revolutionizing mental healthcare by
developing new and innovative next-generation psychedelic-based
treatment options, today announced that Doug Drysdale, Cybin’s
Chief Executive Officer, will be speaking at the 27th Annual Milken
Institute Global Conference on a panel entitled “Collaborating for
Improved Mental Health.” The Conference will take place May 5-8,
2024, at the Beverly Hilton in Los Angeles, and the panel will be
held on Wednesday, May 8, 2024, at 10:00 a.m. PDT.
“The Milken Institute Global Conference focuses on numerous
global challenges across multiple domains, and we are thrilled to
be part of the important conversation addressing today’s mental
health crisis,” stated Doug Drysdale, Cybin’s Chief Executive
Officer. “The Conference provides a meaningful platform to exchange
ideas with global thought leaders and share our vision for
transforming the treatment paradigm for mental health. With the
recent receipt of FDA Breakthrough Therapy Designation for CYB003,
our deuterated psilocybin analog for the adjunctive treatment of
major depressive disorder entering a Phase 3 trial around mid-year;
and CYB004, our deuterated DMT program in Phase 2 development for
the treatment of generalized anxiety disorder, we are excited to
share the groundbreaking work that Cybin is carrying out with the
goal of bringing improved therapeutic options for treating mental
health conditions.”
The live panel discussion and archived webcast will be available
on the Company’s investor relations website on the Events &
Presentations page. For more information on the Milken Institute
and the upcoming conference visit www.milkeninstitute.org.
About Cybin
Cybin is a clinical-stage biopharmaceutical company on a mission
to create safe and effective psychedelic-based therapeutics to
address the large unmet need for new and innovative treatment
options for people who suffer from mental health conditions.
Cybin’s goal of revolutionizing mental healthcare is supported
by a network of world-class partners and internationally recognized
scientists aimed at progressing proprietary drug discovery
platforms, innovative drug delivery systems, and novel formulation
approaches and treatment regimens. The Company is currently
developing CYB003, a proprietary deuterated psilocybin analog for
the treatment of major depressive disorder and CYB004, a
proprietary deuterated DMT molecule for generalized anxiety
disorder and has a research pipeline of investigational
psychedelic-based compounds.
Headquartered in Canada and founded in 2019, Cybin is
operational in Canada, the United States, the United Kingdom, the
Netherlands and Ireland. For company updates and to learn more
about Cybin, visit www.cybin.com or follow the team on X, LinkedIn,
YouTube and Instagram.
Cautionary Notes and Forward-Looking Statements
Certain statements in this news release relating to the Company
are forward-looking statements and are prospective in nature.
Forward-looking statements are not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as “may”, “should”, “could”, “intend”,
“estimate”, “plan”, “anticipate”, “expect”, “believe” or
“continue”, or the negative thereof or similar variations.
Forward-looking statements in this news release include statements
regarding the Company’s proprietary drug discovery platforms,
innovative drug delivery systems, novel formulation approaches and
treatment regimens for mental health disorders.
These forward-looking statements are based on reasonable
assumptions and estimates of management of the Company at the time
such statements were made. Actual future results may differ
materially as forward-looking statements involve known and unknown
risks, uncertainties, and other factors which may cause the actual
results, performance, or achievements of the Company to materially
differ from any future results, performance, or achievements
expressed or implied by such forward-looking statements. Such
factors, among other things, include: implications of the spread of
COVID-19 on the Company's operations; fluctuations in general
macroeconomic conditions; fluctuations in securities markets;
expectations regarding the size of the psychedelics market; the
ability of the Company to successfully achieve its business
objectives; plans for growth; political, social and environmental
uncertainties; employee relations; the presence of laws and
regulations that may impose restrictions in the markets where the
Company operates; and the risk factors set out in each of the
Company's management's discussion and analysis for the three and
nine month periods ended December 31, 2023, and the Company’s
annual information form for the year ended March 31, 2023, which
are available under the Company's profile on www.sedarplus.ca and
with the U.S. Securities and Exchange Commission on EDGAR at
www.sec.gov. Although the forward-looking statements contained in
this news release are based upon what management of the Company
believes, or believed at the time, to be reasonable assumptions,
the Company cannot assure shareholders that actual results will be
consistent with such forward-looking statements, as there may be
other factors that cause results not to be as anticipated,
estimated or intended. Readers should not place undue reliance on
the forward-looking statements and information contained in this
news release. The Company assumes no obligation to update the
forward-looking statements of beliefs, opinions, projections, or
other factors, should they change, except as required by law.
Cybin makes no medical, treatment or health benefit claims about
Cybin’s proposed products. The U.S. Food and Drug Administration,
Health Canada or other similar regulatory authorities have not
evaluated claims regarding psilocybin, psychedelic tryptamine,
tryptamine derivatives or other psychedelic compounds. The efficacy
of such products has not been confirmed by approved research. There
is no assurance that the use of psilocybin, psychedelic tryptamine,
tryptamine derivatives or other psychedelic compounds can diagnose,
treat, cure or prevent any disease or condition. Rigorous
scientific research and clinical trials are needed. Cybin has not
conducted clinical trials for the use of its proposed products. Any
references to quality, consistency, efficacy and safety of
potential products do not imply that Cybin verified such in
clinical trials or that Cybin will complete such trials. If Cybin
cannot obtain the approvals or research necessary to commercialize
its business, it may have a material adverse effect on Cybin’s
performance and operations.
Neither the Cboe Canada nor the NYSE American LLC stock exchange
have approved or disapproved the contents of this news release and
are not responsible for the adequacy and accuracy of the contents
herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240425438704/en/
Investor & Media: Gabriel Fahel Chief Legal Officer
Cybin Inc. 1-866-292-4601 irteam@cybin.com – or –
media@cybin.com